Tag Archives: NCCN Guidelines

Important information to know – from screening to diagnosis for colorectal cancer

Tips From a Member of Our Medical Advisory Board Al B. Benson III, MD, FACP FASCO is Professor of Medicine, Feinberg School of Medicine,  and Associate Director for Clinical Investigations, Robert H. Lurie Comprehensive Cancer Center, Northwestern University One of the nation’s most respected experts in colorectal cancer, Dr. Benson has supported and worked with Fight Colorectal Cancer for years as an active member of our Medical Advisory Board.   Written by Dr. Al Benson, March 18 2013, Chicago, Illinois Although March is Colorectal Cancer Awareness Month, this disease is so frequent yet in most cases preventable that we should be striving every month of the year to make even more people

Cancer-Related Fatigue: Real, Treatable, and Under-Treated

Life-altering fatigue will affect 80% of people getting chemotherapy or radiation therapy, plus most people who have metastatic cancer, and even many survivors long after treatment is done. Yet fatigue in cancer patients has been under-reported, under-diagnosed, and under-treated, according to an expert panel convened by the National Comprehensive Cancer Network (NCCN) a decade ago to recommend cancer-related fatigue treatment guidelines. Some good news: A recent Dutch study published in the Journal of Clinical Oncology found that advanced cancer patients can get significant relief from serious fatigue, when their fatigue and other symptoms are regularly monitored and treated according to guidelines. Some less good news: A small U.S. study published

Erbitux Approved as First-Line Treatment

The FDA has approved Erbitux™ (cetuximab) in combination with FOLFIRI for first-line treatment of patients with metastatic colorectal cancer whose tumors have a wild-type (WT) KRAS gene.  Erbitux was first approved in 2004 for patients whose cancer was not responding to available treatments. FDA’s action was prompted by results from a look back at patient outcomes and KRAS status from three trials: CRYSTAL:  phase 3, 1217 patients newly diagnosed with metastatic CRC, comparing FOLFIRI vs FOLFIRI + Erbitux OPUS: phase 2, 337 patients newly diagnosed with metastatic CRC, comparing FOLFOX vs FOLFOX + Erbitux CA225025: phase 3, 572 patients with metastatic CRC that stopped responding to available treatments, comparing Best Supportive

Colorectal Cancer News in Brief: December 21

Briefly It’s been tested, and it hurts less to rip a bandaid off fast. NCCN has updated their guidelines for colon and rectal cancer to include testing for BRAF mutations in patients with metastatic colorectal cancer. FDA announced a recall of some lots of Alka-Seltzer Plus Day and Night Cold Formula, and an aggressive program to manage respiratory infections at the Seattle Cancer Care Alliance has kept patients there from getting H1N1 flu.

Top